Evidence map›Paper›PMID 40002271›Full record

ArticleCancers2025

Surgery Versus Stereotactic Radiotherapy in Patients over 75 Years Treated for Stage IA-IIA NSCLC.

Galdric Oliver, Mohamed Boucekine, Anne-Laure Couderc, Alex Fourdrain, Audrey Zaccariotto, Isabelle Pougnet, Bertrand Kaeppelin, Pascal Alexandre Thomas, Laetitia Padovani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Galdric OliverOncology Radiotherapy Department, CRCM Inserm, Genome Instability and Carcinogenesis, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, 13284 Marseille, France.ORCID 0009-0000-3809-3319
Mohamed BoucekineCenter for Studies and Research on Health Services and Quality of Life, Aix Marseille University, 13284 Marseille, France.
Anne-Laure CoudercInternal Medicine, Geriatric and Therapeutic Unit, University Hospital (AP-HM), 270 Boulevard de Sainte Marguerite, 13009 Marseille, France.ORCID 0000-0003-2938-2201
Alex FourdrainDepartment of Thoracic Surgery, Diseases of the Esophagus & Lung Transplantation, Hôpital Nord & CRCM, Inserm UMR 1068, CNRS, UMR 7258, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, 13284 Marseille, France.
Audrey ZaccariottoOncology Radiotherapy Department, CRCM Inserm, Genome Instability and Carcinogenesis, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, 13284 Marseille, France.
Isabelle PougnetOncology Radiotherapy Department, CRCM Inserm, Genome Instability and Carcinogenesis, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, 13284 Marseille, France.
Bertrand KaeppelinOncology Radiotherapy Department, CRCM Inserm, Genome Instability and Carcinogenesis, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, 13284 Marseille, France.
Pascal Alexandre ThomasDepartment of Thoracic Surgery, Diseases of the Esophagus & Lung Transplantation, Hôpital Nord & CRCM, Inserm UMR 1068, CNRS, UMR 7258, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, 13284 Marseille, France.ORCID 0000-0002-3305-6989
Laetitia PadovaniOncology Radiotherapy Department, CRCM Inserm, Genome Instability and Carcinogenesis, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, 13284 Marseille, France.ORCID 0000-0003-3054-6218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLobectomy with lymph node dissection is the gold standard treatment for stage IA-IIA Non-Small Cell Lung Cancer (NSCLC). Surgery is responsible for higher early mortality but offers better overall long-term survival. The patient population concerned is often elderly and combines the comorbidities of smoking and age. Several trials have shown good results of stereotactic radiotherapy (SABR) in terms of local control and tolerance in elderly subjects. Our objective is to study the survival and regional control of patients over 75 years treated by surgery or SABR for localized NSCLC. MATERIALS AND

methodWe conducted a single-center retrospective study between January 2012 and December 2022 including elderly patients who received surgery or SABR for NSCLC less than 5 cm in size, N0, M0. A cumulative comorbidity index was calculated for each patient, considering severity and impact of treatment. We performed subgroup analyses using CART method to identify factors impacting survival and early death.

resultsAfter propensity score matching, 127 operated patients were matched to 85 patients treated with SABR. Overall survival at 1 and 5 years for the operated patients was 83.87% and 47.30% compared with 88.8% and 31.5% in the radiotherapy group (

conclusionsSurgery seems to remain the standard of treatment in terms of overall survival and locoregional recurrence, in a context where SABR nevertheless provides excellent local control and tolerance in the short and long term. In order to improve patient selection, we are proposing for the first time a tool to aid therapeutic decision-making.

Indexed as

elderly patientsFrenchlocalized lung cancerlung surgerypropensity score matchingreal-world evidencestereotactic radiotherapytree-based model

Identifiers

PMID40002271
PMCPMC11853726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.